文献速递自身免疫性与大疱性皮肤病

天疱疮患者中抗利妥昔单抗抗体的临床相关性与生物学效应评估

Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus.
PubMed 文献 · JAMA Dermatol · 2022-01-01

这项Ritux3试验的事后分析纳入42例中重度天疱疮患者,于2010年1月至2015年12月在法国25个皮肤科开展,患者接受利妥昔单抗1000 mg(第1、15天)及第12、18月各500 mg维持输注。31%患者检出抗利妥昔单抗抗体,抗体阳性与阴性组持续完全缓解率无显著差异(85% vs 100%,P=0.15),但抗体阳性者抗桥粒芯糖蛋白3抗体水平更高。

要点

  • 42例接受利妥昔单抗治疗的天疱疮患者中13例(31%)第一年内检出抗利妥昔单抗抗体。
  • 抗体阳性与阴性组持续完全缓解率无显著差异(11/13[85%] vs 20/20[100%],P=0.15)。
  • 仅少数同时具有抗体阳性、利妥昔单抗浓度低、B细胞清除不完全及持续抗DSG3抗体的患者似有高复发风险。

核心结论

  • 抗利妥昔单抗抗体在天疱疮患者中常见,但总体上与患者结局无关;仅少数同时具有抗体阳性、利妥昔单抗浓度低、B细胞清除不完全和持续血清抗DSG3抗体的患者似有高复发风险。

研究设计与样本

  • Ritux3试验的事后分析,2010年1月至2015年12月在法国25个皮肤科开展,纳入42例随机接受利妥昔单抗治疗的中重度天疱疮患者,另招募5例患者用于辅助研究。

主要发现

  • 42例患者中13例(31%)在第一年内血清检出抗利妥昔单抗抗体。
  • 排除12月前复发并接受额外输注的9例后,剩余33例中2例(6.1%)在12月后复发,31例(95.9%)维持持续完全缓解至36月。
  • 持续完全缓解率在抗体阳性组(11/13[85%])与抗体阴性组(20/20[100%])间无显著差异(P=0.15)。
  • 抗体阳性组抗桥粒芯糖蛋白3抗体水平高于抗体阴性组(均值[SD] 30.1[50.9] AU/mL vs 4.0[4.3] AU/mL;P=0.03)。
  • 12月后复发的2例抗体阳性患者利妥昔单抗浓度检测不到、B细胞清除不完全,且抗DSG3抗体水平高于维持持续完全缓解的11例抗体阳性患者(利妥昔单抗均值[SD] 0 ug/mL vs 12.5[2.2] ug/mL;P=0.03;B细胞清除不完全2/2 vs 4/11;P=0.19;抗DSG3抗体均值[SD] 103.5[61.5] AU/mL vs 19.5[11.0] AU/mL;P=0.001)及抗体阴性患者(利妥昔单抗均值[SD] 0 ug/mL vs 13.5[1.8] ug/mL;P=0.02;B细胞清除不完全2/2 vs 5/20;P=0.09;抗DSG3抗体均值[SD] 103.5[61.5] AU/mL vs 4.0[1.0] AU/mL;P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The clinical relevance of antirituximab antibodies (ARAs) in patients with pemphigus who are treated with rituximab (RTX) is currently unknown. OBJECTIVE: To determine the prevalence of ARAs in patients with pemphigus who are treated with RTX and their association with complete remission (CR) and relapse. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the Ritux3 trial was conducted from January 2010 to December 2015 in 25 dermatology departments in France and included 42 patients with moderate-to-severe pemphigus who were randomized to receive treatment with RTX. Five additional patients were recruited for an ancillary study. The proportions of patients who achieved CR or relapsed after an initial treatment cycle of RTX were compared depending on whether patients had ARAs. EXPOSURES: Patients were treated with 1000 mg of RTX on days 1 and 15 and 2 maintenance infusions of 500 mg at months 12 and 18. MAIN OUTCOMES AND MEASURES: Rates of relapse and sustained CR at month 36. Levels of ARAs, antidesmoglein 1/3 antibodies, RTX serum concentrations, and peripheral blood CD19+ B-cell frequency were measured. RESULTS: Of 42 participants with vs without ARAs, the mean (SD) age was 55 (17) years and 56 (17) years, respectively; 25 (59.5%) were women. Antirituximab antibodies were detected in the serum samples of 13 of 42 patients (31%) during the first year. Nine patients who experienced relapse before month 12 were excluded because they received additional infusions and could not be further analyzed. Among the 33 remaining patients, 2 patients (6.1%) experienced relapse after month 12, and 31 (95.9%) maintained a sustained CR until month 36. The rate of sustained CR was not different whether patients had ARAs (11 of 13 [85%]) or not (20 of 20 [100%]) (P = .15). Both groups (ARA+ vs ARA-) also had similar CD19+ B-cell depletion and RTX levels, but patients with ARAs had higher anti-desmoglein 3 antibody (DSG3 Abs) levels compared with those without ARAs (mean [SD], 30.1 [50.9] AU/mL vs 4.0 [4.3] AU/mL; P = .03). The 2 patients with ARAs who experienced relapse after month 12 had an undetectable RTX level, incomplete B-cell depletion, and higher anti-DSG3 Abs level than the 11 patients who maintained a sustained CR with ARAs (RTX mean [SD] concentration, 0 ug/mL vs 12.5 [2.2] ug/mL; P = .03; incomplete B-cell depletion, 2 of 2 vs 4 of 11; P = .19; mean [SD] anti-DSG3 Abs levels, 103.5 [61.5] AU/mL vs 19.5 [11.0] AU/mL; P = .001) or patients without ARAs (mean [SD] RTX concentration, 0 ug/mL vs 13.5 [1.8] ug/mL; P = .02; incomplete B-cell depletion, 2 of 2 vs 5 of 20; P = .09; mean [SD] anti-DSG3 Abs level, 103.5 [61.5] AU/mL vs 4.0 [1.0] AU/mL; P < .001). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that ARAs are frequently detected in patients with pemphigus who are treated with RTX and generally are not associated with patient outcomes. Only a few patients with the combination of ARAs, low RTX concentration, incomplete B-cell depletion, and persistent serum anti-DSG3 Abs seem at high risk of relapse.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lemieux A, Maho-Vaillant M, Golinski ML, et al. Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus. JAMA Dermatol. 2022. PMID: 35731529. doi:10.1001/jamadermatol.2022.2149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。